Rodríguez-Baño J, Navarro M D, Romero L, Muniain M A, Cueto M de, Gálvez J, Perea E J, Pascual A
Sección de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Unviersitario Virgen Macarena, and Departamento de Medicina, Universidad de Sevilla, Sevilla, Spain.
Clin Microbiol Infect. 2008 Feb;14(2):180-3. doi: 10.1111/j.1469-0691.2007.01884.x. Epub 2007 Nov 15.
Risk-factors for bloodstream infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli were investigated using an exploratory case-double control study in which 43 cases (70% producing CTX-M enzymes) were compared with: (i) 86 patients with bacteraemia caused by non-ESBL-producing E. coli; and (ii) 86 hospitalised patients. Previous follow-up as an outpatient, urinary catheterisation and use of oxyimino-beta-lactams or fluoroquinolones were independent risk-factors for ESBL-producing E. coli among patients with E. coli bacteraemia, and previous use of oxyimino-beta-lactams or fluoroquinolones were also independent risk-factors among hospitalised patients. These findings may help in identifying patients at greater risk for bloodstream infection caused by ESBL-producing E. coli in endemic areas.
采用探索性病例-双对照研究,对产超广谱β-内酰胺酶(ESBL)大肠埃希菌引起血流感染的危险因素进行了调查。在该研究中,将43例病例(70%产生CTX-M酶)与以下两组进行了比较:(i)86例由非产ESBL大肠埃希菌引起菌血症的患者;(ii)86例住院患者。在大肠埃希菌菌血症患者中,既往门诊随访、导尿以及使用氧亚氨基-β-内酰胺类或氟喹诺酮类药物是产ESBL大肠埃希菌感染的独立危险因素,在住院患者中,既往使用氧亚氨基-β-内酰胺类或氟喹诺酮类药物也是独立危险因素。这些发现可能有助于识别在流行地区感染产ESBL大肠埃希菌导致血流感染风险更高的患者。